Skip to content

The effect of rosuvastatin in multiple sclerosis

Clinical trial to evaluate the effect of rosuvastatin adjuvant therapy on Sirtuin1 gene expression in the treatment of multiple sclerosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210211050323N2
Enrollment
40
Registered
2021-10-07
Start date
2021-10-03
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of multiple sclerosis by a neurologist Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis No other concomitant inflammatory disease Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL No pregnancy and lactation Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration. Do not use any combination with antioxidant effects in the past month.

Exclusion criteria

Exclusion criteria: Existing evidence based on increased patient disability Consumption of any combination or drug with antioxidant effects except prescription drugs Existence of any cognitive or behavioral disorders that lead to the patient not cooperating.

Design outcomes

Primary

MeasureTime frame
Sirtuin1 gene expression. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Laboratory.

Secondary

MeasureTime frame
Expanded Disability Status Scale (EDSS ) score. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Atminani Esfahani

Hamedan University of Medical Sciences

m.etminani@umsha.ac.ir+98 81 3252 0182

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026